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Background
Patients with Child-Pugh class C or class B cirrhosis and 
persistent bleeding at endoscopy are at high risk for 
treatment failure and a poor prognosis. Th is study evalu-
ated the early use of a transjugular intra hepatic porto-
systemic shunt (TIPS) in such patients.
Methods
Objective: Th e study was conducted to determine whether 
early treatment with extended polytetraﬂ uoro ethylene 
(e-PTFE) can improve outcomes in patients who have 
cirrhosis and acute variceal bleeding and who are at high 
risk for treatment failure and death.
Design: Th e study was a randomized clinical trial.
Setting: Th e study was conducted at nine European centers.
Subjects: Eligible patients had cirrhosis with acute eso-
phageal variceal bleeding. Patients had Child-Pugh class 
C disease (a score of 10 to 13) or class B disease (a score 
of 7 to 9) but with active bleeding at diagnostic endoscopy.
Interventions: Endoscopic band ligation (EBL) or endo-
scopic injection sclerotherapy was applied at the time of 
diagnostic endoscopy in all patients and was performed 
within 12 hours after admission while the patients were 
already receiving vasoactive drugs.
Pharmacotherapy-EBL group: Treatment with vasoactive 
drugs was continued until patients were free of bleeding 
for at least 24 hours and preferably up to 5 days, at which 
point treatment with a non-selective beta-blocker and, 
subsequently, oral nitrate therapy was started.
Early-TIPS group: TIPS was performed within 72 hours 
after diagnostic endoscopy (or, if possible, within the ﬁ rst 
24 hours), and vasoactive drugs were administered until 
then.
Outcomes: Th e primary end-point of the study was a 
composite outcome of failure to control acute bleeding or 
failure to prevent clinically signiﬁ cant variceal re-bleed-
ing within 1 year after enrollment. Secondary end-points 
included mortality at 6 weeks and at 1 year.
Results
During a median follow-up of 16 months, re-bleeding or 
failure to control bleeding occurred in 14 patients in the 
pharmacotherapy-EBL group and in one patient in the 
early-TIPS group (P  =  0.001). Th e 1-year actuarial 
probabilities of remaining free of this composite end-
point were 50% in the pharmacotherapy-EBL group and 
97% in the early-TIPS group (P <0.001). Sixteen patients 
died (12 in the pharmacotherapy-EBL group and four in 
the early-TIPS group; P  =  0.01). Th e 1-year actuarial 
survival rates were 61% in the pharmacotherapy-EBL 
group and 86% in the early-TIPS group (P <0.001). Seven 
patients in the pharmacotherapy-EBL group received 
TIPS as rescue therapy, but four died. Th e number of 
days in the intensive care unit and the percentage of time 
in the hospital during follow-up were signiﬁ cantly higher 
in the pharmacotherapy-EBL group than in the early-
TIPS group. No signiﬁ cant diﬀ erences with respect to 
serious adverse events were observed between the two 
treatment groups.
Conclusions
In the cirrhosis patients who were hospitalized for acute 
variceal bleeding and were at high risk for treatment 
failure, the early use of TIPS was associated with signiﬁ -
cant reductions in treatment failure and in mortality.
Commentary
Mortality from acute variceal bleeding (AVB) remains 
high despite optimum medical and endoscopic therapy 
[1,2]. Treatment with transjugular intrahepatic porto-
systemic shunt (TIPS) is eﬀ ective to control bleed ing in © 2010 BioMed Central Ltd
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this population, but has not increased survival rates, 
likely, as a result of subsequent liver decompen sation 
[3,4]. Th e strongest evidence in favor of performing TIPS 
is for secondary prevention of AVB. Previous studies 
have shown that TIPS decreased the risk of recurrent 
variceal bleeding when compared with ‘failed’ endoscopic 
therapy [5,6]. Th e lack of mortality beneﬁ t and the 
increased rate of hepatic encephalopathy following TIPS 
have limited its use mainly to a salvage therapy [7]. 
Monescillo and colleagues [8] demonstrated im proved 
survival when compared  with medical treatment in 
patients who had a hepatic venous pressure gradient of at 
least 20 mm Hg, who were admitted for variceal bleeding, 
and who subsequently had TIPS within 24  hours. Th e 
study by García-Pagán and colleagues [9] attempts to 
address the role of early TIPS in patients with AVB.
Th e early use of TIPS improved outcomes in a highly 
select group of patients with Child-Pugh class C (a score 
of 10 to 13) or class B (a score of 7 to 9) cirrhosis with 
active variceal bleeding. Th e authors screened a total of 
359 patients, of whom 31 were randomly assigned to the 
pharmacotherapy-EBL (endoscopic band ligation) and 32 
to the early-TIPS group. Th e 1-year actuarial probability 
of remaining free of variceal re-bleeding was signiﬁ cantly 
higher in the early-TIPS group than in the pharmaco-
therapy-EBL group (97% versus 50%; absolute risk 
reduction was 47%, and number needed to treat was 2.1 
patients). Mortality rates were lower in the early-TIPS 
group, and the risk of episodes of hepatic encephalopathy 
was similar in the two groups. Considering these ﬁ nd-
ings, the authors recommended early TIPS in AVB 
patients deemed ‘high risk for treatment failure’ [9].
Th is was a well-designed, multi-center, randomized, 
controlled study with an intention-to-treat analysis. Th e 
objectives and inclusion and exclusion criteria were well 
deﬁ ned, and the follow-up period was adequate. Th e study 
used clinical criteria for consideration of TIPS, whereas 
previous work used the invasively measured parameter of 
hepatic venous pressure gradient. Th e use of expanded 
polytetraﬂ uroethylene (e-PTFE)-covered stents, which are 
associated with reductions in the incidence of TIPS 
dysfunction, is another important diﬀ erence between this 
study and that by Monescillo and colleagues [8].
We would like to point out that only small subsets of 
patients with AVB were recruited (18%), and it took over 
34  months to recruit the 63 patients from nine centers. 
One quarter of patients received sclerotherapy, which is 
generally considered inferior to band ligation in the 
management of AVB [10]. Th e etiology of liver disease in 
over one half of patients in both groups was secondary to 
alcohol, with an overwhelming majority of these patients 
actively drinking. Unless one knows ongoing alcohol use 
after AVB in both groups, one cannot know whether 
abstinence may have played a role in survival rates.
Since the publication of the study, the original authors 
assessed the beneﬁ ts of early TIPS in a follow-up 
retrospective cohort who were managed on the basis of 
the study ﬁ ndings [11]. Th irty patients who received 
medical-EBL therapy were compared with 45 patients 
who received early TIPS. Th e 1- and 2-year actuarial 
probabilities of recurrent variceal bleeding were 7% (95% 
conﬁ dence interval (CI) 2% to 17%) and 7% (95% CI 2% to 
17%) in the early-TIPS group and 47% (95% CI 28% to 
63%) and 51% (95% CI 31% to 67%) in the medical group, 
respectively. Th e 1-year mortality rate was higher in the 
medical-EBL therapy group than in the early-TIPS group 
(30%, 95% CI 15% to 47% versus 14%, 95% CI 6% to 27%; 
P = 0.056). No signiﬁ cant diﬀ erence in the 1-year actuarial 
probability of hepatic encephalopathy was noted.
Th e Baveno V consensus group recommended, on the 
basis of encouraging results, (class 1b; A) TIPS as an early 
treatment for high-risk patients [12]. Despite the 
promising results, we believe that, more than 2  years 
after the publication of the study, a state of equipoise 
continues to exist about the value and role of early TIPS 
versus medical/endoscopic management in the patient 
who presents with AVB. Although the results of the study 
by García-Pagán and colleagues [9] are provocative, 
several key questions remain unanswered. Th e mean 
Model for End-Stage Liver Disease (MELD) scores were 
15.5  ±  5 in the early-TIPS group and 16.9  ±  6.3 in the 
pharmaco therapy-EBL arm, raising a number of 
questions. Should patients with similar Child-Pugh 
scores but higher MELD scores receive early TIPS? 
Should hepatic venous pressure gradient be completely 
ignored, or is there a role for pressure measurements in 
association with clinical criteria for delineating high-risk 
patients? Would the strategy be eﬀ ective in patients with 
cirrhosis from hepatitis C virus or non-alcoholic steato-
hepatitis (NASH), in which the insult for liver injury is 
not so readily removable compared with alcohol, in 
which abstinence may slow progression of liver disease? 
Should we set aside the mountain of evidence that 
showed a high incidence of refractory and debilitating 
encephalopathy in older patients with advanced cirrhosis 
after TIPS?
To put these questions into a real-life clinical scenario, 
consider the following: A 64-year-old with NASH 
cirrhosis, Child-Pugh class C (score of 12), MELD score of 
25, and two prior episodes of encephalopathy in the last 
two months (one of these episodes requiring intubation) is 
admitted with his ﬁ rst variceal bleed. An endoscopy 
reveals medium-sized eso phageal varices, and a clear 
nipple sign is seen in the distal esophagus on the largest 
varix. Band ligation is performed with good decom-
pression. Should this patient be sent for ‘early’ TIPS?
A larger study will be helpful to address these issues. 
Finally, TIPS is a procedure performed by highly trained 
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specialists, and local technical expertise should be a 
crucial factor to use early TIPS in a ‘non-rescue’ situation.
Recommendation
Early TIPS should be considered in AVB after endoscopic 
intervention in patients with Child-Pugh class C (scores 
of 10 to 13) disease or patients with class B (scores of 7 to 
9) disease with active bleeding at initial endoscopy when 
MELD scores are not higher than 22. It must be 
emphasized that the study results do not apply to all 
cirrhosis patients presenting with variceal bleeding.
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